ASX Announcements

Neuren's Phase 2 trial of trofinetide demonstrates significant clinical benefit in pediatric Rett syndrome
Trading Halt
S&P DJ Indices Announces March Quarterly Rebalance
Preliminary Final Report
Investor presentation, 2 February 2017
Appendix 4C - quarterly
Neuren completes Phase 2 trial in pediatric Rett syndrome
Results of Meeting
Investor presentation, 25 November 2016
Notice of special meeting of shareholders